All In Biotech

NDA 213871 · Pfizer

Cibinqo

Abrocitinib · Oral · Janus Kinase Inhibitor

NovelBreakthrough therapyPriority review

CDER novel approval, Jan 14, 2022: To treat refractory, moderate-to-severe atopic dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 14, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

44

11 Phase 3, 9 recruiting

FAERS reports

3,948

1,377 serious, 70 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. ( 5.1 ) • Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA...

What it is approved for

From the label in effect Oct 15, 2026.

CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. ( 1 ) Limitation of Use : CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Mechanism: CIBINQO is a Janus kinase (JAK) inhibitor. Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. In a cell-free isolated enzyme assay, abrocitinib was selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold), as well as the broader kinome. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known. Both the parent compound and the active metabolites inhibit JAK1 activity in vitro with similar levels of selectivity.

Therapeutic areas: Oncology · Immunology and inflammation · Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 14, 2023 Supplement 4 · Efficacy LabelLetter
  • Feb 9, 2023 Supplement 1 · Efficacy · priority review LabelLetter
  • Jan 14, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
3 products under this application
  • CIBINQO · ABROCITINIB 200MG · TABLET, ORAL · Prescription
  • CIBINQO · ABROCITINIB 50MG · TABLET, ORAL · Prescription
  • CIBINQO · ABROCITINIB 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abrocitinib" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective537
  • condition aggravated366
  • off label use323
  • pruritus247
  • therapeutic product effect incomplete208
  • rash184
  • dermatitis atopic179
  • nausea166
  • headache109
  • eczema95
  • acne89
  • fatigue83

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
20202
202111
2022416
20231,084
20241,189
2025967
2026277

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cibinqo (Abrocitinib)

2024 spending

$17.1M

Beneficiaries

536

2,728 claims

Per beneficiary

$31,818

$183.57 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,849,145
2023$9,784,290
2024$17,054,378

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 98 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.